Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC

Diabetes care27 Jan 2010Cited by 85 (Europe PMC)

PMID20107105PMCIDPMC2858197DOI10.2337/dc09-1521PepBankPUB-20107105

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, adding exenatide to rosiglitazone reduced A1C more than rosiglitazone alone.
In plain wordsIn people with diabetes, exenatide plus rosiglitazone reduced A1C more than rosiglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C combination versus rosiglitazone
Study
n: not reported in source
Comparator
rosiglitazone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Measurements
A1C change
−1.3%
EXE+ROSI
A1C change
−1%
ROSI
Source sentences
Summary
RESULTS A1C declined in all groups (P < 0.05), but decreased most with EXE+ROSI (EXE+ROSI, -1.3 +/- 0.1%; ROSI, -1.0 +/- 0.1%, EXE, -0.9 +/- 0.1%; EXE+ROSI vs. EXE or ROSI, P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710502
02HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, exenatide reduced weight while rosiglitazone increased weight.
In plain wordsIn people with diabetes, exenatide reduced weight compared with weight gain with rosiglitazone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight exenatide versus rosiglitazone
Study
n: not reported in source
Comparator
rosiglitazone
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Measurements
Weight change
−2.8 kg
EXE
Weight change
1.5 kg
ROSI
Source sentences
Summary
ROSI resulted in weight gain, while EXE and EXE+ROSI resulted in weight loss (EXE, -2.8 +/- 0.5 kg; EXE+ROSI, -1.2 +/- 0.5 kg; ROSI, + 1.5 +/- 0.5 kg; P < 0.05 between and within all groups).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710504
03HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, exenatide plus rosiglitazone reduced weight while rosiglitazone alone increased weight.
In plain wordsIn people with diabetes, exenatide plus rosiglitazone reduced weight compared with weight gain with rosiglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight combination versus rosiglitazone
Study
n: not reported in source
Comparator
rosiglitazone alone
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Measurements
Weight change
−1.2 kg
EXE+ROSI
Weight change
1.5 kg
ROSI
Source sentences
Summary
ROSI resulted in weight gain, while EXE and EXE+ROSI resulted in weight loss (EXE, -2.8 +/- 0.5 kg; EXE+ROSI, -1.2 +/- 0.5 kg; ROSI, + 1.5 +/- 0.5 kg; P < 0.05 between and within all groups).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710505
04HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, first-phase insulin secretion was higher with exenatide than rosiglitazone.
In plain wordsIn people with diabetes, first-phase insulin release was higher with exenatide than rosiglitazone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFirst-phase insulin secretion exenatide
Study
n: not reported in source
Comparator
rosiglitazone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710507
05HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, second-phase insulin secretion was higher with exenatide than rosiglitazone.
In plain wordsIn people with diabetes, second-phase insulin release was higher with exenatide than rosiglitazone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSecond-phase insulin secretion exenatide
Study
n: not reported in source
Comparator
rosiglitazone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710508
06HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, exenatide plus rosiglitazone increased first-phase insulin secretion compared with rosiglitazone alone.
In plain wordsIn people with diabetes, exenatide plus rosiglitazone increased first-phase insulin release compared with rosiglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFirst-phase insulin secretion combination
Study
n: not reported in source
Comparator
rosiglitazone alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710509
07HumanRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, exenatide plus rosiglitazone increased second-phase insulin secretion compared with rosiglitazone alone.
In plain wordsIn people with diabetes, exenatide plus rosiglitazone increased second-phase insulin release compared with rosiglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSecond-phase insulin secretion combination
Study
n: not reported in source
Comparator
rosiglitazone alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg b.i.d. · 20 weeksAs given in this study (human).
Source sentences
Summary
At week 20, 1st and 2nd phase insulin secretion was significantly higher in EXE and EXE+ROSI versus ROSI (both P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
Report a problemFND-2010710510

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes on metformin, A1C declined in all groups, including exenatide alone.
In plain wordsIn people with diabetes on metformin, A1C declined in all groups, including exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C change with exenatide alone
Study
n = 45
Outcome group
Glycemic control · Metabolic and weight
Measurements
A1C change
−0.9%
EXE
Source sentences
Summary
RESULTS A1C declined in all groups (P < 0.05), but decreased most with EXE+ROSI (EXE+ROSI, -1.3 +/- 0.1%; ROSI, -1.0 +/- 0.1%, EXE, -0.9 +/- 0.1%; EXE+ROSI vs. EXE or ROSI, P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2010710501
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, exenatide plus rosiglitazone reduced A1C more than exenatide alone.
In plain wordsIn people with diabetes, exenatide plus rosiglitazone reduced A1C more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C combination versus exenatide
Study
n: not reported in source
Comparator
exenatide alone
Outcome group
Glycemic control · Metabolic and weight
Measurements
A1C change
−1.3%
EXE+ROSI
A1C change
−0.9%
EXE
Source sentences
Summary
RESULTS A1C declined in all groups (P < 0.05), but decreased most with EXE+ROSI (EXE+ROSI, -1.3 +/- 0.1%; ROSI, -1.0 +/- 0.1%, EXE, -0.9 +/- 0.1%; EXE+ROSI vs. EXE or ROSI, P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2010710503
10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, exenatide plus rosiglitazone produced less weight loss than exenatide alone.
In plain wordsIn people with diabetes, exenatide plus rosiglitazone produced less weight loss than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBody weight combination versus exenatide
Study
n: not reported in source
Comparator
exenatide alone
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−1.2 kg
EXE+ROSI
Weight change
−2.8 kg
EXE
Source sentences
Summary
ROSI resulted in weight gain, while EXE and EXE+ROSI resulted in weight loss (EXE, -2.8 +/- 0.5 kg; EXE+ROSI, -1.2 +/- 0.5 kg; ROSI, + 1.5 +/- 0.5 kg; P < 0.05 between and within all groups).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2010710506
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In participants with type 2 diabetes, insulin sensitivity was higher with exenatide plus rosiglitazone than exenatide alone.
In plain wordsIn people with diabetes, insulin sensitivity was higher with exenatide plus rosiglitazone than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity
Study
n: not reported in source
Comparator
exenatide alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin sensitivity (M value) was significantly higher in EXE+ROSI versus EXE (P = 0.014).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 20-week, randomized, open-label, multicenter study, participants (mean age, 56 +/- 10 years; weight, 93 +/- 16 kg; A1C, 7.8 +/- 0.7%) continued their metformin regimen and received either EXE 10 microg b.i.d. (n = 45), ROSI 4 mg b.i.d. (n = 45), or EXE 10 microg b.i.d. + ROSI 4 mg b.i.d. (n = 47).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2010710511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00135330

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

AstraZenecan = 137Oct 2005 to Jul 2008

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.